• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia.

作者信息

Parry Helen, Bruton Rachel, Roberts Thomas, McIlroy Graham, Damery Sarah, Sylla Panagiota, Dowell Alexander C, Tut Gokhan, Lancaster Tara, Bone David, Willett Brian, Logan Nicola, Scott Sam, Hulme Sam, Jadir Azar, Amin Umayr, Nicol Sam, Stephens Christine, Faustini Sian, Al-Taei Saly, Richter Alex, Blakeway Daniel, Verma Kriti, Margielewska-Davies Sandra, Pearce Hayden, Pratt Guy, Zuo Jianmin, Paneesha Shankara, Moss Paul

机构信息

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.

出版信息

Cancer Cell. 2022 Jun 13;40(6):584-586. doi: 10.1016/j.ccell.2022.05.001. Epub 2022 May 6.

DOI:10.1016/j.ccell.2022.05.001
PMID:35588735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9072807/
Abstract
摘要

相似文献

1
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia.新冠病毒疫苗在慢性淋巴细胞白血病中引发强大的细胞免疫和临床保护作用。
Cancer Cell. 2022 Jun 13;40(6):584-586. doi: 10.1016/j.ccell.2022.05.001. Epub 2022 May 6.
2
COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.新型冠状病毒肺炎疫苗接种：慢性淋巴细胞白血病患者加强剂量后的体液免疫和细胞免疫评估
Hematol Oncol. 2023 Aug;41(3):559-562. doi: 10.1002/hon.3121. Epub 2023 Jan 9.
3
Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.BNT162b2 mRNA COVID-19 疫苗对慢性淋巴细胞白血病患者体液和细胞免疫的影响。
Hematol Oncol. 2023 Feb;41(1):120-127. doi: 10.1002/hon.3077. Epub 2022 Sep 30.
4
mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.慢性淋巴细胞白血病患者接种新型冠状病毒 mRNA 疫苗：一项系统评价与荟萃分析。
Eur J Haematol. 2022 Mar;108(3):264-267. doi: 10.1111/ejh.13729. Epub 2021 Dec 13.
5
Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者 COVID-19 疫苗失败的原因和后果。
Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.
6
SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者第三次接种新冠疫苗后针对严重急性呼吸综合征冠状病毒2的细胞反应
Haematologica. 2022 Oct 1;107(10):2480-2484. doi: 10.3324/haematol.2022.280982.
7
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对新冠病毒mRNA疫苗的细胞免疫和体液免疫反应
Blood Adv. 2022 Feb 22;6(4):1207-1211. doi: 10.1182/bloodadvances.2021006633.
8
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.2019冠状病毒病疫苗接种：慢性淋巴细胞白血病患者疫苗接种失败风险评估
Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30.
9
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者接种新冠疫苗后针对严重急性呼吸综合征冠状病毒2的特异性细胞反应
Leukemia. 2022 Feb;36(2):562-565. doi: 10.1038/s41375-021-01500-1. Epub 2021 Dec 22.
10
SARS-CoV-2 vaccination in CLL: how often is enough?慢性淋巴细胞白血病患者的新冠病毒 2 型疫苗接种：接种频率多少才足够？
Blood. 2022 Dec 22;140(25):2655-2657. doi: 10.1182/blood.2022018586.

引用本文的文献

1
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia.慢性淋巴细胞白血病患者接种二价新冠病毒加强疫苗后奥密克戎特异性免疫反应的增强
Blood Cancer J. 2024 Jan 25;14(1):22. doi: 10.1038/s41408-023-00940-5.
2
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?慢性淋巴细胞白血病患者中的新冠病毒肺炎：我们了解到了什么？
Acta Haematol. 2024;147(1):60-72. doi: 10.1159/000534540. Epub 2023 Oct 11.
3
Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.B 细胞血液恶性肿瘤患者对 SARS-CoV-2 的体液和细胞反应随着连续接种疫苗而改善。
Br J Haematol. 2023 Sep;202(6):1091-1103. doi: 10.1111/bjh.18962. Epub 2023 Jul 4.
4
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.慢性淋巴细胞白血病患者在奥密克戎大流行期间对SARS-CoV-2疫苗的抗体反应及COVID-19易感性：一项多中心研究的两年随访
Cancers (Basel). 2023 May 30;15(11):2993. doi: 10.3390/cancers15112993.
5
Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy.接受泽布替尼治疗的患者对 COVID-19 疫苗接种免疫反应的前瞻性综合分析。
EJHaem. 2023 Jan 20;4(1):216-220. doi: 10.1002/jha2.639. eCollection 2023 Feb.
6
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.B 细胞靶向治疗的癌症患者中新型 SARS-CoV-2 疫苗抗体反应的选择性抑制。
JCI Insight. 2023 Mar 22;8(6):e163434. doi: 10.1172/jci.insight.163434.
7
Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8 T cell immunity in CLL and MDS patients.BNT162b2 COVID-19 mRNA 疫苗三剂接种可在 CLL 和 MDS 患者中建立持久的 CD8 T 细胞免疫。
Front Immunol. 2023 Jan 10;13:1035344. doi: 10.3389/fimmu.2022.1035344. eCollection 2022.
8
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.2019冠状病毒病疫苗接种反应及其在慢性淋巴细胞白血病患者中的实际应用
Hemasphere. 2022 Dec 20;7(1):e811. doi: 10.1097/HS9.0000000000000811. eCollection 2023 Jan.
9
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.在患有 B 细胞淋巴瘤和多发性骨髓瘤的个体中，COVID-19 疫苗接种后可产生高效价高亲和力中和抗体和 T 细胞应答。
Nat Cancer. 2023 Jan;4(1):81-95. doi: 10.1038/s43018-022-00502-x. Epub 2022 Dec 21.
10
Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.慢性淋巴细胞白血病患者接种第四剂 BNT162b2 mRNA COVID-19 疫苗后的细胞和体液反应。
Eur J Haematol. 2023 Jan;110(1):99-108. doi: 10.1111/ejh.13878. Epub 2022 Oct 23.

本文引用的文献

1
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.接种两针和三针疫苗后 B 细胞恶性肿瘤患者对 SARS-CoV-2 变异体的免疫应答：英国 PROSECO 研究。
Nat Cancer. 2022 May;3(5):552-564. doi: 10.1038/s43018-022-00364-3. Epub 2022 Mar 24.
2
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.接种疫苗的 B 细胞慢性淋巴细胞白血病患者对 SARS-CoV-2 德尔塔变异株的中和能力受损。
J Hematol Oncol. 2022 Jan 9;15(1):3. doi: 10.1186/s13045-021-01219-7.
3
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.癌症患者接种疫苗后对 SARS-CoV-2 关注变体的适应性免疫和中和抗体：CAPTURE 研究。
Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.
4
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.三剂 BNT162b2 mRNA COVID-19 疫苗在标准两剂接种失败的 CLL 患者中的疗效。
Blood. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085.
5
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者：欧洲血液学协会调查（EPICOVIDEHA）。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
6
Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines.新冠疫苗引发的免疫反应的差异动力学
N Engl J Med. 2021 Nov 18;385(21):2010-2012. doi: 10.1056/NEJMc2115596. Epub 2021 Oct 15.
7
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies.B细胞源性血液系统恶性肿瘤患者对SARS-CoV-2加强疫苗接种的抗刺突抗体反应
Cancer Cell. 2021 Oct 11;39(10):1297-1299. doi: 10.1016/j.ccell.2021.09.001. Epub 2021 Sep 7.
8
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.